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TRANSPLANT arteriosclerosis is the most serious 
complication of successful cardiac transplantation. 1.2 
Improvements in cardiac graft survival after transplanta-
tion have led to the recognition of a proliferative, occlusive 
arteriosclerosis in the coronary arteries of the graft. In 
rats, this arteriosclerosis is the result of chronic. immune-
mediated rejection reaction.3 Manipulation of the recipient 
immune responses results in alterations in the expression 
of the disease. Effective immunosuppression with cyclo-
sporine (CyA), for example. can prevent the development 
of the lesions.4 There have been recent reports, however, 
that FK 506 may be responsible for stimulating. rather than 
preventing. transplant arteriosclerosis in rats.5 We have 
recently evaluated the influence of FK 506 treatment on 
the development of transplant arteriosclerosis in the LEW-
to-F344 rat allograft model. These studies were designed to 
establish whether (I) FK 506 alone will induce arterioscle-
rosis in syngeneic grafts and (2) whether the treatment of 
cardiac allograft recipients with minimal levels of FK 506 
will interfere with or prevent the development of trans-
plant arteriosclerosis. 
MATERIALS AND METHODS 
Animals 
Adult male LEW (RTf') and F344(RTI iVi) rats (Harlan Sprague 
Dawley, Indianapolis, Ind) weighing 220 to 240 g were used as 
donors and recipients for these experiments. The recipients of 
heterotopic cardiac grafts were assigned to four experimental 
groups: group I (N = 14), untreated controls (vehicle only); group 
2 (N = 10). oral FK 506 (1.0 mg/kg/d); group 3 (N = 9). oral eyA 
(5 mg/kg/d); group 4 (N = 7), syngeneic (F344) cardiac grafts and 
oral FK 506 (I mg/kg/d). 
Cardiac Transplantation 
The procedure of heterotopic cardiac transplantation used in this 
study is a modification of the technique originally described by 
Ono and Lindsey. 6 The graft was implanted in the abdominal 
cavity with both anastomoses done in a running end-to-side 
fashion with 10-0 Novafil on a TE-70 needle. Operative times 
ranged from 30 to 45 minutes with a success rate of approximately 
90%. The grafts were evaluated for function by daily abdominal 
palpation daily and rejection confirmed by laparotomy. All grafts 
were removed for examination at day 90 posttransplantation and 
a detailed histopathologic examination of the lesions conducted. 
Immunohistochemistry 
Monoclonal antibodies (MAbs) specific for Pan T cells (OX19); T 
helper cells (W3125); T cytotoxic/suppressor cells (OX8); macro-
phages (ED-I), and smooth muscle cells (ASM-I) were used to 
characterize the arteriosclerotic lesions. Immunoperoxidase stud-
ies were performed using a three-step indirect method. 7 
. :,': 
Histopathologic Evaluation 
Histologic grades for recording severity of the lesions present in 
the donor myocardium consisted of scoring lesions as: O. normal; 
I, mild; 2. moderate: and 3, severe. Quantitation ofthe number of 
inflammatory cell subsets in the myocardium of the grafts was 
performed by light microscopic observation. Five randomly cho-
sen fields were examined for each MAb and the mean cell count 
was expressed as the number of cellslhigh power field (HPF). 
RESULTS 
Treatment of allograft recipients with low levels of FK 506 
or Cy A was associated with improved graft survival and a 
marked reduction in the severity of the inflammatory 
infiltrate in the grafts. Allograft survival varied between 
the treatment groups with a high survival rate 90 days 
posttransplantation in group 2 (FK 506 treatment, 90%). 
group 3 (CyA treatment, 100%), and group 4 (syngeneic 
grafts, 100%). Of 14 animals included in the untreated 
controls (group I), 8 grafts were rejected by the recipients 
at 50 to 70 days posttransplantation. Six (42.8%) grafts 
survived the full 90 days posttransplantation. The im-
proved graft survival following immunosuppression with 
Cy A and FK 506 was associated with a reduction in the 
degree of vascular intimal proliferation. perivascular infil-
tration, myocardial inflammation, and fibrosis (Table I, Fig 
1). There was no evidence of vascular intimal proliferation 
or other transplant-associated inflammatory lesions in the 
syngeneic F344 grafts treated with FK 506. 
Immunohistochemical examination of the inflammatory 
cell subset distribution in the myocardium of the grafts 
demonstrated that both FK 506 and Cy A decreased the 
number of infiltrating leukocytes, particularly macro-
phages and cytotoxic T cells, when compared with the 
control group. 
DISCUSSION 
Recent reports from both clinical and experimental studies 
have indicated that transplant arteriosclerosis is the result 
of a chronic, low-grade immune response of recipient to 
donor graft histocompatibility antigens.7.s The ability of 
immunosuppressive agents, such as CyA. to prevent the 
From the Transplantation Biology Laboratory, Department of 
Surgery, Cedars-Sinai Medical Center, Los Angeles, CA; and the 
Department of Surgery, University of Pittsburgh, PittSburgh, Penn-
sylvania. 
Address reprint requests to Guo-Du Wu, MD, Transplantation 
Biology Laboratory, Cedars-Sinai Medical Center, 150 North Rob-
ertson Blvd, Suite 250 N. Beverly Hills, CA 90211. 
© 1991 by Appleton & Lange 
0041-1345/911$3.001+0 
3272 Transplantation Proceedings, Vol 23, No 6 (December), 1991: pp 3272-3274 
FK 506 INHIBITS ARTERIOSCLEROSIS 3273 
Table 1. Severity of the Pathologic Changes Observed in LEW-to-F344 Cardiac Allografts 
Histopathologic Lesions" 
Group (No.) VIP PVF MI MF 
Group 1 
Control (6) 2.68 :t 0.18 1.92:t 0.55 2.00:to 0.54 2.17 :t 0.26 
Group 2 
FK 506 (9) 1.64 :t 0.30t 1.06:t 0.58 1.38:to 0.47 1.30 :to 0.49 
Group 3 
CyA(9) 1.74 :t 0.38t 1.25 :to 0.71 1.3O:to 0.41 1.35 ± 0.68 
Group 4 
Syngeneic (7) 0.00 0.00 0.30 ±0.20 0.00 
Abbreviations: VIP. vascular intimal proliferation: PVF, penvascular fibrosis: MI. myocardial inflammation: MF, myocardial fibrosis. 
"The values represent the mean score (0,0 to 3.0) lor the lesions within each group:!: SO. 
tlndicates differences 01 P < ,05 when compared with control values (Student's ttest). 
intimal proliferative lesions in experimental animals is 
consistent with therapeutic control of the chronic immune 
reaction. The same effect of CyA therapy has not been 
consistently observed in patients with successful heart 
Fig 1. (A) Histopathologic changes present in allograft 90 days 
posttransplantation after treatment with FK 506 with mild vascular 
intimal proliferation and perivascular mononuclear cell infiltration 
(EVG stain: original magnification, x400). (B) Untreated allografts 
exhibit severe intimal thickening in coronary arteries (immunoper-
oxidase stain for a actin: original magn~ationI x 400). 
grafts.9 The severity of arteriosclerotic lesions frequently 
displays little correlation with the number of rejection 
episodes. the degree of HLA matching, or the use of 
immunosuppressive drugs. In rats. the most severe vascu-
lar lesions occur in strain combinations in which weak 
histocompatibility differences allow for prolonged survival 
of the graft with minimal evidence of active rejection. The 
apparent lack of correlation of immunosuppression with 
the development of arteriosclerosis in patients may repre-
sent weak histocompatibility differences that stimulate the 
proliferative lesions without precipitating clinically appar-
ent episodes of acute rejection. 
FK 506 is a new and potent immunosuppressive drug 
that is similar in its mode of action to Cy A. 10.11 Recent 
reports, however, have provided evidence for the devel-
opment of vasculitis in dogs l2 and transplant arterioscle-
rosis in rats. 5 The data presented here demonstrate that 
FK 506 inhibits the development of transplant arterioscle-
rosis in rats. These results are consistent with the immu-
nosuppressive activity of the drug and the reduction in the 
severity of the pathologic lesions present in the grafts. 
They are also in general agreement with the expected 
results for a drug with immunosuppressive activity similar 
to that ofCyA. The levels ofCyA and FK 506 used in these 
studies were chosen to be minimally effective therapeutic 
doses to mimic the clinical management of the transplant 
patient. Both drugs significantly inhibited the development 
of the arteriosclerosis. Neither compound. however. com-
pletely prevented the development of the transplant le-
sions at the dose levels used. There was no evidence of the 
appearance of vascular lesions in syngeneic grafts of 
recipients treated with FK 506. These results demonstrate 
that FK 506 acts as an immunosuppressive agent to 
prevent transplant arteriosclerosis in experimental animals 
and does not independently stimulate the development of 
vascular lesions. 
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